Inovalon, Inc. operates as a data analytics technology company that combines analytics with targeted interventions focusing on clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. It delivers data-driven solutions and identifies gaps in care, quality, data integrity, and financial performance. The company provides solutions for risk adjustment, clinical and quality outcomes, healthcare effectiveness data and information set (HEDIS) reporting, and electronic health record (EHR) interoperability. It offers HEDIS Advantage, a solution for measurement and reporting of clinical and quality outcomes; Star Advantage, a solution for full-service qual...
4321 Collington Road
Bowie, MD 20716
Founded in 1998
Elderplan Selects Inovalon's Data Driven Platform to Improve Medicare Advantage And FIDA Outcomes
Oct 14 14
Inovalon, Inc. announced that it has expanded its relationship and entered into a multi-year relationship with Elderplan, Inc. Elderplan will implement Inovalon's quality improvement, predictive analytics, risk score accuracy and business intelligence solutions to provide an integrated suite for identifying and closing gaps in care, quality, assessment, and documentation for its membership population.
Inovalon, Inc. Presents Quality Measurement Research Related to Heart Treatment Procedures
Jun 5 14
Inovalon, Inc. announced the presentation of results from the study 'Thirty-day Incidence of Cardiac Tamponade and Mortality Following Catheter or Surgical Ablation of Atrial Fibrillation' at the Council on Quality of Care and Outcomes Research (QCOR) on June 4, 2014 in Baltimore, Maryland. The risks of mortality and cardiac tamponade (a constriction of the heart muscle from blood swelling inside the area surrounding the heart) during the first 30 days following catheter or surgical atrial fibrillation (AF) ablation are not well known. The study found that the thirty-day incidence of cardiac tamponade was 1.74% and was higher for surgical ablation than catheter ablation. The thirty-day mortality rate was 1.15%, which was also higher for surgical ablation than catheter ablation. According to the authors, these findings provide new comparative safety information that can help inform optimal treatment practices and could serve as the basis for a physician level or facility level quality measure designed to evaluate relative performance and provide benchmarks to support both consumer choice and quality improvement efforts.
Inovalon Expands Executive Leadership Team
May 19 14
Inovalon, Inc. announced the appointment of Robert Wychulis as President and Thomas Kloster, CPA, as Chief Financial Officer. With significant ongoing growth and record first quarter performance, the additions to Inovalon's executive team further supports the company's drive to bring high impact, advanced analytics to the point-of-care across the dynamic and rapidly expanding healthcare landscape. Effective May 19, 2014, Mr. Bob Wychulis will serve as President of Inovalon., a role split off by Dr. Keith Dunleavy, who has held the position of President along with Chief Executive Officer and Chairman of the Board since the company's founding. In this newly delineated role, Mr. Wychulis will serve as the general manager of the Company, ultimately responsible for all aspects of the Company's goals and commitments around day-to-day product and service delivery, performance, support, and client value achievement. Keith Dunleavy, M.D., who has led Inovalon as President, Chief Executive Officer, as well as Chairman of the Board since Inovalon's origin, will continue to serve as Chief Executive Officer and Chairman of the Board. Mr. Wychulis joins Inovalon after serving as the President of the WellPoint New York government program health plan, HealthPlus, an Amerigroup company, where he was responsible for the full P&L management of the company's $1.9 billion product portfolio within the New York region. Mr. Wychulis was responsible for oversight of medical management, quality improvement, finance, compliance, human resources, government relations, provider contracting, marketing, enrollment, strategic planning, and the managed long-term care product, and played a pivotal role in working with state regulators in transforming New York's Medicaid delivery system through the state's Medicaid Redesign Team (MRT). In addition to Mr. Wychulis joining the Inovalon Executive Leadership Team, effective April 1, 2014, Mr. Tom Kloster, CPA, joined the Company as Chief Financial Officer. In this role, Mr. Kloster is responsible for the oversight of all financial activities and relationships of the Company. Prior to joining Inovalon, Mr. Kloster served as the Chief Financial Officer at Algeco Scotsman. Both Mr. Wychulis and Mr. Kloster will report to Keith Dunleavy, M.D.